BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 21145399)

  • 1. Experimental approaches to the interaction of the prion protein with nucleic acids and glycosaminoglycans: Modulators of the pathogenic conversion.
    Silva JL; Vieira TC; Gomes MP; Rangel LP; Scapin SM; Cordeiro Y
    Methods; 2011 Mar; 53(3):306-17. PubMed ID: 21145399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intriguing nucleic-acid-binding features of mammalian prion protein.
    Silva JL; Lima LM; Foguel D; Cordeiro Y
    Trends Biochem Sci; 2008 Mar; 33(3):132-40. PubMed ID: 18243708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prion protein self-interactions: a gateway to novel therapeutic strategies?
    Rigter A; Langeveld JP; van Zijderveld FG; Bossers A
    Vaccine; 2010 Nov; 28(49):7810-23. PubMed ID: 20932496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nucleic acid and prion protein interaction produces spherical amyloids which can function in vivo as coats of spongiform encephalopathy agent.
    Nandi PK; Nicole JC
    J Mol Biol; 2004 Nov; 344(3):827-37. PubMed ID: 15533448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of RNA in mammalian prion protein conversion.
    Gomes MP; Vieira TC; Cordeiro Y; Silva JL
    Wiley Interdiscip Rev RNA; 2012; 3(3):415-28. PubMed ID: 22095764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conformational conversion of prion protein in prion diseases.
    Zhou Z; Xiao G
    Acta Biochim Biophys Sin (Shanghai); 2013 Jun; 45(6):465-76. PubMed ID: 23580591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural insights into the interaction between prion protein and nucleic acid.
    Lima LM; Cordeiro Y; Tinoco LW; Marques AF; Oliveira CL; Sampath S; Kodali R; Choi G; Foguel D; Torriani I; Caughey B; Silva JL
    Biochemistry; 2006 Aug; 45(30):9180-7. PubMed ID: 16866364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of genuine prion infectivity by serial PMCA.
    Weber P; Giese A; Piening N; Mitteregger G; Thomzig A; Beekes M; Kretzschmar HA
    Vet Microbiol; 2007 Aug; 123(4):346-57. PubMed ID: 17493773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNA molecules stimulate prion protein conversion.
    Deleault NR; Lucassen RW; Supattapone S
    Nature; 2003 Oct; 425(6959):717-20. PubMed ID: 14562104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prions and transmissible spongiform encephalopathy (TSE) chemotherapeutics: A common mechanism for anti-TSE compounds?
    Caughey B; Caughey WS; Kocisko DA; Lee KS; Silveira JR; Morrey JD
    Acc Chem Res; 2006 Sep; 39(9):646-53. PubMed ID: 16981681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Biology of non-conventional transmissible agents or prions].
    Dormont D
    Rev Neurol (Paris); 1998 Feb; 154(2):142-51. PubMed ID: 9773035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prions at the crossroads: the need to identify the active TSE agent.
    Nandi PK
    Bioessays; 2004 May; 26(5):469-73. PubMed ID: 15112226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The highways and byways of prion protein trafficking.
    Campana V; Sarnataro D; Zurzolo C
    Trends Cell Biol; 2005 Feb; 15(2):102-11. PubMed ID: 15695097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prion protein oligomer and its neurotoxicity.
    Huang P; Lian F; Wen Y; Guo C; Lin D
    Acta Biochim Biophys Sin (Shanghai); 2013 Jun; 45(6):442-51. PubMed ID: 23557632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strain-specific effects of reducing agents on the cell-free conversion of recombinant prion protein into a protease-resistant form.
    Imamura M; Kato N; Okada H; Iwamaru Y; Shimizu Y; Mohri S; Yokoyama T
    Microbiol Immunol; 2011 Sep; 55(9):633-40. PubMed ID: 21645053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experimental approaches to TSE prevention via inhibition of prion formation.
    Politopoulou G
    Protein Pept Lett; 2004 Jun; 11(3):249-55. PubMed ID: 15182226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unraveling the details of prion (con)formation(s): recent advances by mass spectrometry.
    Principe S; Maras B; SchininĂ  ME; Pocchiari M; Cardone F
    Curr Opin Drug Discov Devel; 2008 Sep; 11(5):697-707. PubMed ID: 18729021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 25 nm virion is the likely cause of transmissible spongiform encephalopathies.
    Manuelidis L
    J Cell Biochem; 2007 Mar; 100(4):897-915. PubMed ID: 17044041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prion protein has DNA strand transfer properties similar to retroviral nucleocapsid protein.
    Gabus C; Auxilien S; PĂ©choux C; Dormont D; Swietnicki W; Morillas M; Surewicz W; Nandi P; Darlix JL
    J Mol Biol; 2001 Apr; 307(4):1011-21. PubMed ID: 11286552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prion protein interconversions.
    Caughey B
    Philos Trans R Soc Lond B Biol Sci; 2001 Feb; 356(1406):197-200; discussion 200-2. PubMed ID: 11260800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.